Grow Funds, an investment Advisor, released its Q1 2026 investor letter for “GROW Small Cap Equity Long/Short Fund”.
A copy of the letter can be downloaded here
In Q1 2026, GROW Small Cap Equity Long/Short L.P (Fund) returned 4.18%, outperforming the Russell 2000 Growth Index’s –2.80%, HFRI Equity Hedge Index’s -0.24%, and the HFRI Fundamental Growth Index’s 0.47% returns. Long positions and hedges, and short positions, safeguarded the portfolio amid the volatility driven by the Iran War. In addition, please check the Strategy’s top five holdings to know its best picks in 2026.
In its first-quarter 2026 investor letter, Grow Funds highlighted Profound Medical Corp. (NASDAQ:PROF). Profound Medical Corp. (NASDAQ:PROF) is a Canada based commercial-stage medical device company that focuses on developing AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. On June 18, 2026, Profound Medical Corp. (NASDAQ:PROF) closed at $6.87 per share.